Engene announces oversubscribed $200 million private placement financing

Financing included participation from new and existing investors pro forma cash and cash equivalents expected to fund current operating plan into 2027 boston and montreal , feb. 14, 2024 /prnewswire/ - engene holdings inc. (nasdaq: engn or "engene" or the "company"), a clinical-stage genetic medicines company whose non-viral lead program eg-70 is in a pivotal study for bcg-unresponsive non-muscle invasive bladder cancer (nmibc), today announced that it has agreed to sell 20 million of its common shares at a price per share of $10.00, representing a 31% premium over the closing price on february 13, 2024. the financing is expected to close on february 16, 2024, subject to customary closing conditions.
ENGN Ratings Summary
ENGN Quant Ranking